The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients After Total Knee Arthroplasty

• Status: Not yet recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, patients scheduled to undergo total knee arthroplasty (TKA) will be screened through a survey for patients with central sensitivity and patients with neuropathic pain as preoperative evaluation.

It is designed to evaluate the effectiveness of pregabalin with the decision to prescribe duloxetine by dividing patient groups according to central sensitization and neuropathic pain.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Catholic University of Korea
• Treatments: Duloxetine Hydrochloride; Pregabalin

Criteria

Inclusion Criteria:

• Patients for total knee arthroplasty over the age of 19

• Patients who have the will or ability to follow the doctor's instructions, including rehabilitation treatment such as joint exercise.

• Patients understand this study and agree in writing by the patient's own or by the patient's representative to participate in the study.

• Patients with central sensitization and neuropathic pain.

Exclusion Criteria:

• Rheumatoid arthritis

• Other inflammatory arthritis

• Neuropsychiatric patients

• Hepatic insufficiency

• Renal insufficiency

• Allergy or intolerance to study medications

• Patients with an acetylsalicylic acid of IV (angina, congestive heart failure, dementia, cerebrovascular accident)

• Chronic gabapentin or pregabalin use (regular use for longer than 3 months)

• Chronic opioid use (taking opioids for longer than 3 months)

• Alcohol, drug abuser

• Narcotics addiction